1. Russell Scott, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael d'Emden, Dana Tse, Maria-Riitta Taskinen, Christian Ehnholm, Anthony Keech, on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetes Care 32:493-498
2. Miller M, Cannon CP, Murphy SA et al, PROVE-IT TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 trial. J Am Coll Cardiol 2008; 51: 724-30.
3. Barter PJ, Gotto AM, LaRosa JC et al, Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301-10.
4. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final report. Circulation 2002;106: 3143-21.
5. Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
6. Keech AC, Mitchell P, Summanen PA, et al, FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007;370:1687-97.
7. Colman P, Rajamani K, Li L-P et al. Benefits of long-term fenofibrate therapy on amputations in type 2 diabetes mellitus in the FIELD trial. Presented at the European Association for the study of Diabetes (EASD), Rome, September 2008.
8. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Lancet. 2008 Jan 12;371(9607):117-25.
For further information contact: New Zealand: Professor Russell Scott, Lipid & Diabetes Research Group, Christchurch Hospital, Christchurch, +64-(3)-364-0449 or 0640, +64-(274)-366-380. Australia; Associate Professor Richard O'Brien, Clinical School, Austin Hospital, Heidelberg, +61-(3)-9496-5585 +61-(0)415-550-183, Professor Greg Fulcher, Northern Clinical School, Royal North Shore Hospital, +61-(0)2-9926-8388, +61-(0)438-878-962, firstname.lastname@example.org